Lonza has extended two ongoing collaborations with unnamed major biopharmaceutical companies. One covers the commercial-scale filling of antibody-drug conjugates (ADCs), the other bioconjugation. Financial details were not disclosed in either case.

As part of the former partnership, Lonza will build a dedicated line at its site in Stein, Switzerland, for the aseptic filling of highly potent ADCs and lyophilisation under containment. The new line is expected to be operational in 2027 and to create about 115 new jobs at peak capacity.

Lonza is to expand its Early Development Services (EDS) offering into North America with a new, laboratory in Cambridge, Massachusetts. Covering nearly 1,600 m², this will begin operations in May. No details were given on the expenditure involved.

Like the company’s other EDS lab in Cambridge, UK, the new lab will offer early in silico non-GMP protein expression and in vitro immunosafety assessment services. These will mainly be delivered to the preclinical stage small- to mid-sized biotechs around the Boston area.

Lonza has recently announced three specific investments in the pharma sector in recent weeks. It will build two new customer-dedicated conjugation suites for antibody-drug conjugates (ADCs) at Visp, Switzerland, while adding particle engineering and drug product development at two sites in the US.